1 Min Read
Jan 9 (Reuters) - Vivus Inc :
* On Jan 3, co entered into a settlement agreement with hetero - sec filing
* Vivus- Settlement resolves co's lawsuit in response to Hetero's filing of ANDA, seeking to market generic versions of Stendra before expiration of asserted patents
* Vivus - under settlement agreement, hetero was granted license to manufacture, commercialize generic version of stendra described in its ANDA filing in U.S.
* Vivus - settlement agreement provides for full settlement of all claims asserted in suit, subject to court's acceptance of stipulation of dismissal Source text (bit.ly/2i7clUY) Further company coverage: